Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vivacta to Present Poster at the 44th Oak Ridge Conference

Published: Wednesday, April 11, 2012
Last Updated: Wednesday, April 11, 2012
Bookmark and Share
Emerging technologies for 21st century clinical diagnostics.

Vivacta Limited has announced that it will be presenting a poster at the Oak Ridge Conference: Emerging Technologies for 21st Century Clinical Diagnostics, taking place in San Jose, USA, on 19th-20th April 2012.

The Oak Ridge Conference is the American Association for Clinical Chemistry’s annual forum for emerging clinical diagnostic technologies, and brings together thought leaders from industry, academia, and clinical laboratories. The conference focuses exclusively on pre-commercial technologies.

Vivacta's piezofilm technology platform enables the development of next generation near-patient diagnostic products using a novel immunoassay system for the measurement of analytes in whole-blood.

Each diagnostic test requires only a finger prick sample, providing actionable results within 10 minutes or less.

The poster describes refinements in Vivacta's piezofilm technology platform, particularly in relation to the company’s troponin assay although the benefits apply to the system as a whole.

According to the poster, novel conjugation methods for the attachment of antibodies and small molecules to carbon particles increase the binding capacity of the carbon-antibody conjugates 5-fold, giving much improved signal-to-noise.

As a result, Vivacta has achieved a sensitivity of 10 pg / mL (picograms per millilitre) for its troponin I assay using a 30µL sample.

Dr Aileen McGettrick, Team Leader of the troponin programme at Vivacta presenting at the conference said: "The Oak Ridge conference is renowned for attracting leading scientists and technologists to present their latest successes across a range of cutting-edge disciplines including diagnostics. I am delighted that the organizers have accepted our poster for presentation at the meeting."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Immune System 'On Switch' Breakthrough Could Lead to Targeted Drugs
A crucial 'on switch' that boosts the body's defenses against infections has been successfully identified in new scientific research.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!